Tech Company Financing Transactions
Zyngenia Funding Round
Zyngenia, operating out of Washington, secured $10 million from New Enterprise Associates and private investors.
Transaction Overview
Company Name
Announced On
12/31/2009
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
New Enterprise Associates (Robert Garland)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1050 Connecticut Ave. NW 500
Washington, DC 20036
USA
Washington, DC 20036
USA
Phone
Website
Email Address
Overview
At Zyngenia, we are developing the next generation of antibody-based drugs called Zybody therapeutics. We are spearheading the development of this novel class of drugs to create more potent and more broadly acting protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Parkinson
Chief Scientific Officer
David Hilbert
Vice President
Viktor Roschke
Browse more venture capital transactions:
Prev: 12/31/2009: eTelemetry venture capital transaction
Next: 12/31/2009: Inviragen venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs